Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Oryza Pharmaceuticals
AddedFeb 17, 2024
UpdatedJun 18, 2026
Oryza Pharmaceuticals

Oryza Pharmaceuticals

Public

Oryza Pharmaceuticals: Developing, manufacturing, and marketing quality pharmaceutical products.

HQ
Coral Springs, FL, US
Founded
2016
Overview
Compare
Fundraising
Employees
Website

Oryza Pharmaceuticals is dedicated to developing, manufacturing, and marketing high-quality pharmaceutical products. The company focuses on creating innovative solutions to meet the healthcare needs of diverse markets. By leveraging advanced research and development, Oryza aims to provide effective and accessible medications that improve patient outcomes.

Oryza Pharmaceuticals has made significant strides in the pharmaceutical industry, gaining recognition for its commitment to quality and innovation. The company's products are distributed widely, contributing to better health standards globally. Through strategic partnerships and a robust distribution network, Oryza continues to expand its impact in the healthcare sector.

Oryza Pharmaceuticals - Quick Facts

When was Oryza Pharmaceuticals founded?

Oryza Pharmaceuticals was founded in 2016.

Where is Oryza Pharmaceuticals' headquarters located?

Oryza Pharmaceuticals' headquarters is located in Coral Springs, FL, US.

When was Oryza Pharmaceuticals' last funding round?

Oryza Pharmaceuticals' most recent funding round was for $10M (USD) in November 2023.

How much has Oryza Pharmaceuticals raised to-date?

As of Nov 22, 2023, Oryza Pharmaceuticals has raised a total of $10M (USD).

How many employees does Oryza Pharmaceuticals have?

Oryza Pharmaceuticals has 175 employees as of Feb 4, 2024.

Oryza Pharmaceuticals - Classification

Ownership
  • Public
Technology
  • SaaS
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Pharmaceuticals
Tags
  • Biotech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
Show 11 more industry codes
NAICS
  • 456000Health and Personal Care Retailers
  • 450000Retail Trade
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
  • 456100Health and Personal Care Retailers
  • 456110Pharmacies and Drug Retailers
SIC
  • 5900Miscellaneous Retail
  • 8000Health Services
  • 5910Drug Stores And Proprietary Stores
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified